The first phase of Sunshine Act disclosures left drugmakers uneasy, Ed Silverman writes. Companies encountered formatting problems that led to the rejection of submissions and they experienced confusion about assigning financial values. Drugmakers are also worried about possible discrepancies in the second phase, which started this month and will require more specific reporting.

Related Summaries